

CONTENTS

	Pages
Acknowledgement	c
Abstract in Thai	d
Abstract in English	f
List of Tables	k
List of Figures	m
List of Abbreviations	o
Chapter 1 Introduction	1
1.1 Historical Background	1
1.2 Objective	3
1.3 Literature review	3
1.3.1 Human immunodeficiency virus (HIV) infection and Acquired immune deficiency syndrome (AIDS)	3
1.3.1.1 HIV structure and replication	3
1.3.1.2 HIV classification	6
1.3.1.3 Transmission of HIV infection	8
1.3.1.4 HIV-1 Mother-to-child transmission (MTCT)	9
1.3.1.5 Pediatric HIV-1 infection	9
1.3.2 Diagnosis of HIV infection in infants and children	11
1.3.3 Prevention of mother-to-child transmission (PMTCT)	14
1.3.4 HIV treatment	17
1.3.4.1 Antiretroviral (ARV) drugs	17
1.3.4.2 Antiretroviral treatment in children	20
1.3.5 Antiretroviral drug resistance	21


	Pages
1.3.5.1 Mechanism of resistance	22
1.3.5.2 Effect of antiretroviral drug resistance to children	25
1.3.5.3 HIV drug resistance testing	26
1.3.6 The current situation of HIV drug resistance in children	27
Chapter 2 Materials and Methods	31
2.1 Research design	31
2.2 Materials and methods	33
2.2.1 Study population	33
2.2.2 DNA extraction	34
2.2.3 HIV-1 drug resistance determination	35
2.2.3.1 Amplification of polymerase gene	35
2.2.3.2 Protease and Reverse transcriptase region sequencing	38
2.2.3.3 Analyzing and editing of nucleotide sequences	38
2.2.3.4 Interpretation of drug resistance mutation	39
2.2.4 HIV-1 genotyping	39
2.2.4.1 The Stanford HIVdb Program Genotypic Resistance Interpretation Algorithm	39
2.2.4.2 REGA HIV-1 subtyping tool	39
2.2.5 Statistical analysis	39
2.2.6 Ethical approval	40
Chapter 3 Results	41
3.1 Baseline characteristics of HIV-1 infected infants	41
3.2 Amplification of HIV reverse transcriptase and protease gene	45
3.3 Sequence analysis	46
3.4 Interpretation of HIV drug resistance mutation (DRM) among newly HIV-1 infected infants	48
3.4.1 HIV DRMs profiles on reverse transcriptase region	61

	Pages
3.4.2 HIV DRM profiles on protease region	64
3.4.3 Drug susceptibility interpretation	65
3.5 Genetic subtype of HIV-1 among patients	68
3.5.1 The Stanford HIVdb Program Genotypic Resistance Interpretation Algorithm	68
3.5.2 REGA HIV-1 Subtyping analysis	69
3.6 The infants and maternal factor analysis	70
Chapter 4 Discussion	76
Chapter 5 Conclusion	83
References	84
List of publications	103
Appendices	104
Appendix A Nucleic acid codes, amino acid codes, and genetic codes	105
Appendix B Summary of HIV-1 drug resistance mutations	108
Appendix C List of the chemicals and reagents	131
Appendix D List of the instruments	132
Appendix G Reagent preparations	133
Curriculum Vitae	134

LIST OF TABLES

	Page
Table 1.1 The categorization of risk criteria and recommended diagnosis for early infant diagnosis.	13
Table 1.2 The prevention guideline of mother-to-child transmission in Thailand.	16
Table 1.3 The antiretroviral drugs currently approved by FDA.	18
Table 1.4 The recommendations of ART treatment regimen in children in Thailand.	21
Table 1.5 Major mutations Involved in Resistance of HIV to ARV drugs.	23
Table 2.1 The number of children, who were born from HIV-1 infected mothers and attended for Early HIV-1 Infant Diagnosis at the Division of Clinical Microbiology, Chiang Mai University, from 2007 to 2014, and registered hospital.	34
Table 2.2 The sequence of oligonucleotide primers.	36
Table 3.1 The characteristics and demographic of 288 HIV-infected infants in this study.	43
Table 3.2 Prevalence of drug resistant mutations (DRMs) to drug class family in HIV infected infants.	49
Table 3.3 HIV-1 DRMs profiles, predicted ARV resistance and ARV exposure data among HIV-1 infected infants.	53
Table 3.4 Reverse transcriptase inhibitors resistant mutations in HIV infected infants.	63
Table 3.5 Protease inhibitors resistant mutations in infected infants.	65
Table 3.6 HIV-1 subtype by The Stanford HIVdb Program Genotypic Resistance Interpretation Algorithm.	68
Table 3.7 HIV-1 subtype results by REGA HIV-1 Subtyping Tool.	69

		Page
Table 3.8	The association of characteristics and demographic parameters and HIV-1 NRTI, NNRTI, and PI major DRMs among HIV-1 infected infants.	73
Table 6.1	Nucleic acid codes.	105
Table 6.2	Amino acid codes.	106
Table 6.3	Resistance mutation comments (Stanford HIVDR database).	110



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
 Copyright© by Chiang Mai University
 All rights reserved

LIST OF FIGURES

	Page
Figure 1.1	3
Figure 1.2.	4
Figure 1.3	6
Figure 1.4	8
Figure 2.1	32
Figure 2.2	37
Figure 3.1	46
Figure 3.2	47
Figure 3.3	50
Figure 3.4	51
Figure 3.5	52
Figure 3.6	67
Figure 3.7	71
Figure 4.1	78
Figure 6.1	107

LIST OF ABBREVIATIONS

°C	Degree celcius
3TC	Lamivudine
95% CI	95% confidence interval
AA	Amino acid
ABC	Abacavir
ADR	Acquired drug resistance
AIDS	Acquired immune deficiency syndrome
ANC	Antenatal care
APV	Amprenavir
ART	Antiretroviral therapy
ARV	Antiretroviral
ATV/r	Atazanavir/ritonavir
AZT, ZDV	Zidovudine
bp	base pair
CCR5	CC chemokine receptor 5
CD4+	CD4 T lymphocyte
CDC	United States Centers for Disease Control and Prevention
CNS	Central nervous system
CRF	Circulating Recombinant Form
CXCR4	CXC chemokine receptor 4
d4T	Stavudine
DBS	Dried blood spot
ddC	Zalcitabine
ddI	Didanosine
DLV	Delavirdine
DNA	Deoxyribonucleic acid
DRMs	Drug resistance mutations

DRV/r	Darunavir/ritonavir
DTG	Dolutegravir
EFV	Efavirenz
EID	Early infant diagnosis
ETR	Etravirine
EVG/r	Elvitegravir/ritonavir
FDA	Food and Drug Administration
FPV/r	Fosamprenavir/ritonavir
FTC	Emtricitabine
GAZT	Azidothymidine glucuronide
gp	Glycoprotein
HAART	Highly Active Antiretroviral Therapy
HIV	Human immunodeficiency virus
HIVDR	HIV drug resistance
HLA	Human leukocyte antigen
IDV	Indinavir
IN	Integrase
IVDU	Intravenous drug users
kb	Kilobase
LPV/r	Lopinavir/ritonavir
MDR	Multidrug-resistance
mL	Milliliter
MTCT	Mother-to-child transmission
MVC	Maraviroc
NAP	National AIDS Program
NFV	Nefinavir
NGS	Next-generation sequencing
NHSO	National Health Security Office of Thailand.
nm	Nanometer
NNRTI	Non-nucleoside reverse transcriptase inhibitor
NRTI	Nucleoside reverse transcriptase inhibitor

NVP	Nevirapine
OIs	Opportunistic infection
PBMC	Peripheral blood mononuclear cell
PCP	<i>Pneumocystis carinii</i> pneumonia
PCR	Polymerase chain reaction
PI	Protease inhibitor
PIC	Preintegration complex
PMTCT	Prevention of mother-to-child transmission of HIV
PR	Protease
RAL	Raltegravir
RNA	Ribonucleic acid
RPV	Rilpivirine
RT	Reverse transcriptase
RTV	Ritonavir
sd-NVP	Single-dose nevirapine
SQV/r	Saquinavir/ritonavir
T-20	Enfuvirtide
TAMs	Thymidine analogue mutations
TDF	Tenofovir disoproxil fumarate
TDR	Transmitted drug resistance
TPV/r	Tipranavir/ritonavir
UNAIDS	Joint United Nations Programme on HIV/AIDS
WHO	World Health Organization